Regulatory News
Tuesday, January 10, 2017
BRIEF-Coherus Biosciences announces positive topline 24-week treatment Phase 3 results for CHS-1420 in patients with Psoriasis
* Coherus Biosciences announces positive topline 24-week
treatment phase three results for CHS-1420 (HUMIRA biosimilar
candidate) in patients with Psoriasis
Read more
No comments:
Post a Comment
Newer Post
Older Post
Home
View mobile version
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment